The notification from Nasdaq is a negative signal indicating that Homology Medicines is currently not meeting the exchange's minimum bid price requirement. This could lead to a decrease in investor confidence and a potential decline in the stock price in the short term. The consideration of a reverse stock split is a remedial action, but it also suggests that the company's stock is under pressure, which could further impact investor sentiment negatively.